<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="3487">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on October 07, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04356144</url>
  </required_header>
  <id_info>
    <org_study_id>TGA-TM-Critical-2019</org_study_id>
    <nct_id>NCT04356144</nct_id>
  </id_info>
  <brief_title>Thrombomodulin-modified Thrombin Generation Assay (TGA-TM) in Patients With Critical Infections</brief_title>
  <official_title>Coagulation Assays in the Critically Ill Patient: a New Approach Using the Thrombomodulin-modified Thrombin Generation Assay (TGA-TM)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Medical University of Vienna</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Medical Scientific Fund of the Mayor of Vienna</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Medical University of Vienna</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Inflammation and abnormalities in laboratory coagulation tests are inseparably tied. For
      example, coagulation abnormalities are nearly universal in septic patients. Coagulation
      disorders have also been reported in many patients with severe courses of Coronavirus disease
      2019 (Covid-19). But it is difficult to assess these changes. Global coagulation tests have
      been shown to incorrectly assess in vivo coagulation in patients admitted to intensive care
      units. But other tests are available. Thrombin generation assay (TGA) is a laboratory test
      which allows the assessment of an individual's potential to generate thrombin. But also in
      conventional TGA the protein C system is hardly activated because of the absence of
      endothelial cells (containing natural thrombomodulin) in the plasma sample. Therefore the
      investigators add recombinant human thrombomodulin to a conventional TGA. Thereby the
      investigators hope to be able to depict in vivo coagulation more closely than global
      coagulation tests do.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 15, 2020</start_date>
  <completion_date type="Anticipated">December 1, 2020</completion_date>
  <primary_completion_date type="Anticipated">October 1, 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>ETP (AUC) without rhThrombomodulin (rhTM)</measure>
    <time_frame>6 months</time_frame>
    <description>nM;</description>
  </primary_outcome>
  <primary_outcome>
    <measure>ETP (AUC) with rhThrombomodulin (rhTM)</measure>
    <time_frame>6 months</time_frame>
    <description>nM;</description>
  </primary_outcome>
  <primary_outcome>
    <measure>ETP-ratio</measure>
    <time_frame>6 months</time_frame>
    <description>Ratio of endogenous thrombin potential (ETP) with rhTM to ETP without rhTM</description>
  </primary_outcome>
  <primary_outcome>
    <measure>ETP-Normalisation</measure>
    <time_frame>6 months</time_frame>
    <description>Comparison of ETP-ratios from ICU patients and ETP-ratios from citrated plasma samples from healthy donors</description>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Disseminated Intravascular Coagulation</condition>
  <condition>Critical Illness</condition>
  <condition>Sars-CoV2</condition>
  <condition>Viral Infection</condition>
  <condition>Coagulation Disorder, Blood</condition>
  <condition>Covid19</condition>
  <arm_group>
    <arm_group_label>Critical infection</arm_group_label>
    <description>Patients with signs of infection with SARS-CoV-2 or already diagnosed infection with SARS-CoV-2 admitted to the ICU</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Thrombin Generation Assay (TGA)</intervention_name>
    <description>TGA via a fluorimetric module. Coagulation cascade is activated upon addition of different concentrations of tissue factor and phospholipids. The fluorogenic substrate Z-Gly-Gly-Arg-AMC (ZGGR-AMC) is cleaved by formed thrombin over time. By plotting the changes in fluorescence as a function of time (cnt/min), it depicts the &quot;Thrombin Generation Curve&quot; (thrombin generated - plotted against time). The area under the thrombin curve is defined as the endogenous thrombin potential (ETP).</description>
    <arm_group_label>Critical infection</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Thrombomodulin Modified Thrombin Generation Assay (TGA-TM)</intervention_name>
    <description>Recombinant Human Thrombomodulin (TM) is added to the conventional TGA. When recombinant TM is added, the protein C system is fully activated and therefore the ETP obtained reflects both the anti- and procoagulant factors.</description>
    <arm_group_label>Critical infection</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        60 critically ill patients with signs of infection with SARS-CoV2 or proven infection with
        SARS-CoV-2 admitted to Intensive Care Units (ICU).
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Admission to ICU

          -  Clinical signs of infection with SARS-CoV-2 or already diagnosed infection with
             SARS-CoV-2

          -  Neutrophil-Lymphocyte Ratio (NLR) &gt;3

        Exclusion Criteria:

          -  Intake of oral anticoagulants or any kind of parenteral therapeutic anticoagulation
             prior to ICU admission

          -  Congenital coagulation disorder

          -  Treatment with Prothrombin complex concentrate (F. II, VII, IX, X) or activated
             Prothrombin complex within past 48 hours

          -  Treatment with recombinant factor VIIa (e.g. eptacog alfa) within past 48 hours

          -  Treatment with recombinant protein C within past 48 hours

          -  Active bleeding

          -  Acute myocardial infarction

          -  HIV infection

          -  Chronic pancreatitis

          -  Liver cirrhosis
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Lukas Infanger, MD</last_name>
    <phone>+43140400</phone>
    <phone_ext>41070</phone_ext>
    <email>lukas.infanger@meduniwien.ac.at</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Marion Wiegele, MD</last_name>
    <phone>+43140400</phone>
    <phone_ext>41070</phone_ext>
    <email>marion.wiegele@meduniwien.ac.at</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Medical University Vienna</name>
      <address>
        <city>Vienna</city>
        <zip>1090</zip>
        <country>Austria</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lukas Infanger, MD</last_name>
      <phone>+43140400</phone>
      <phone_ext>41070</phone_ext>
      <email>lukas.infanger@meduniwien.ac.at</email>
    </contact>
  </location>
  <location_countries>
    <country>Austria</country>
  </location_countries>
  <verification_date>May 2020</verification_date>
  <study_first_submitted>April 15, 2020</study_first_submitted>
  <study_first_submitted_qc>April 18, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">April 22, 2020</study_first_posted>
  <last_update_submitted>May 1, 2020</last_update_submitted>
  <last_update_submitted_qc>May 1, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">May 5, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Medical University of Vienna</investigator_affiliation>
    <investigator_full_name>Lukas Infanger</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>TGA</keyword>
  <keyword>thrombin generation</keyword>
  <keyword>Sars-CoV2</keyword>
  <keyword>ROTEM</keyword>
  <keyword>rotational thromboelastometry</keyword>
  <keyword>viscoelastic assay</keyword>
  <keyword>thrombomodulin</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infection</mesh_term>
    <mesh_term>Virus Diseases</mesh_term>
    <mesh_term>Hemostatic Disorders</mesh_term>
    <mesh_term>Blood Coagulation Disorders</mesh_term>
    <mesh_term>Disseminated Intravascular Coagulation</mesh_term>
    <mesh_term>Critical Illness</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Thrombin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

